Crossmark

Assembly of In-Situ Gel Containing Nano-Spanlastics of an Angiotensin II Inhibitor as a Novel Epitome for Hypertension Management: Factorial Design Optimization, In-vitro Gauging, Pharmacokinetics, and Pharmacodynamics Appraisal

Crossref DOI link: https://doi.org/10.1208/s12249-024-02823-9

Published Online: 2024-05-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Salem, Heba F.

Nafady, Mohamed M.

Eissa, Essam M.

Abdel-Sattar, Hend Hassan

Khallaf, Rasha A. https://orcid.org/0000-0001-7885-1946
Funding

Funding for this research was provided by:

Beni Suef University
License Information

Text and Data Mining valid from 2024-05-16

Version of Record valid from 2024-05-16
More Information

Article History

Received: 6 February 2024

Accepted: 29 April 2024

First Online: 16 May 2024

Declarations

:

: Under the institutional criteria of the Nahda University for Experimental Animals, Beni-Suef, Egypt's Animal Ethics Committee, and with approval number NUB-023–011, the <i>in-vivo</i> investigations were carried out. The study fulfilled the ARRIVE Declaration and the regulations for the use and care of animals.

: After reviewing this work, all authors have approved its publication.

: The writers disclosed no competing interests.

Document is current

Any future updates will be listed below